Boxlight Corp Regains Nasdaq Compliance; One-Year Monitor Imposed

What Happened

• On September 2, 2026, Boxlight Corporation (BOXL) announced a Nasdaq Hearings Panel decision that the company has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the $2,500,000 stockholders’ equity requirement) and granted continued listing on The Nasdaq Stock Market. The Panel hearing took place on August 13, 2026.
• The Panel’s decision noted Boxlight’s compliance plan, which included a PIPE Series D Convertible Preferred Stock financing that yielded approximately $6.6 million in net proceeds (Tranche One closed August 5, 2026, raising $4.8 million net of fees), an anticipated $15 million equity line of credit, and a planned $2.9 million debt-to-equity swap.
• Pursuant to Nasdaq Listing Rule 5815(d)(4)(A), the Panel imposed a one-year Discretionary Panel Monitor effective August 17, 2026. During the Monitoring Period, Nasdaq Staff must issue a Delist Determination Letter if the company is found out of compliance (without allowing a cure period), at which point Boxlight may request a new hearing.

Key Details

• Panel Decision date: September 2, 2026.
• Nasdaq requirement: $2,500,000 minimum stockholders’ equity (Rule 5550(b)(1)).
• Financing: Series D PIPE net proceeds ~ $6.6M; Tranche One closed Aug 5, 2026 — $4.8M net.
• Ongoing measures: anticipated $15M equity line of credit and planned $2.9M debt-to-equity swap.
• Monitor & review rights: One-year discretionary monitor effective Aug 17, 2026; Boxlight may seek review by the Nasdaq Listing and Hearing Review Council within 15 days (fee $15,000); the Council may self-initiate review within 45 days.

Why It Matters

• Regaining compliance preserves Boxlight’s Nasdaq listing for now, avoiding immediate delisting.
• The one-year discretionary monitor increases regulatory scrutiny: if Boxlight falls out of compliance during the Monitoring Period, Nasdaq Staff can move directly toward delisting without allowing the usual cure period.
• Investors should watch the company’s remaining financing steps (equity line, debt-to-equity swap, completion of the Series D) because those measures are central to maintaining compliance and the Nasdaq listing.